Market Currents
More on Amgen (AMGN): Q1 beats across the board on strong sales growth and better margins....
-
Tuesday, April 24, 2012, 5:11 PM ETMore on Amgen (AMGN): Q1 beats across the board on strong sales growth and better margins. Combined sales of Neulasta and Neupogen +9%, Xgeva +14%, and Prolia +9%. Operating margins rose to 36.4% from 34.9%.
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
